Skip to main content
TipRanks
Go Ultimate75% OFF

Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

1 Followers
IN:NECLIFE

Nectar Lifesciences Ltd.

(NSE:NECLIFE)

Select Model
Rating:47Neutral
Price Target:INR 10.00â–²(0.20% Upside)
Action:upgraded
Date:08/27/26

Low score driven primarily by weak financial performance with revenue volatility and losses; positive technical momentum offers limited support while unattractive valuation constrains the rating.

Positive Factors
Business DiversificationExposure to APIs, finished dosage formulations, and contract activities gives Nectar multiple pharmaceutical revenue avenues. This breadth can support product and customer diversification over time, reducing reliance on any single offering if execution and demand remain stable.
Negative Factors
Revenue CollapseA collapse to zero revenue represents a severe disruption to the company’s commercial operations and removes the scale needed to absorb fixed costs. Unless revenue is restored, the business may face continuing operating losses, weaker bargaining power, and reduced ability to fund development.

Nectar Lifesciences Ltd. (NECLIFE) vs. iShares MSCI India ETF (INDA)

-40%-20%0%20%40%60%IN:NECLIFE-34.34%INDA-4.08%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.94B
Dividend Yield
―
Average Volume (3M)
28.04K
Price to Earnings (P/E)
-2.9
Beta (1Y)
1.28
Revenue Growth
-99.85%
EPS Growth
78.93%
Country
India
Employees
111
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing ser...

How the Company Makes Money

Nectar Lifesciences Ltd. makes money primarily by selling pharmaceutical products to customers (typically including other pharmaceutical companies, distributors, and institutional buyers depending on the product category). Key revenue streams general...

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Volatile revenues, persistent net losses, declining assets and equity, with inconsistent cash flows despite debt reduction efforts.

Income Statement

25Negative

Balance Sheet

40Negative

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Jun 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue74.43M20.11M16.70B16.84B15.24B16.69B
Gross Profit-567.25M-590.34M3.02B4.82B579.91M2.99B
EBITDA83.68M-289.51M-245.66M1.69B994.97M1.61B
Net Income-2.45B-2.93B-1.14B49.95M-241.83M250.47M
Balance Sheet
Total Assets06.22B20.47B21.91B21.89B23.91B
Cash, Cash Equivalents and Short-Term Investments1.25B1.25B272.63M203.01M178.94M182.35M
Total Debt005.82B6.36B7.54B8.60B
Total Liabilities-5.82B393.11M10.91B11.22B11.25B13.03B
Stockholders Equity5.82B5.82B9.56B10.69B10.65B10.88B
Cash Flow
Free Cash Flow1.44B-3.61B1.26B1.95B1.04B700.35M
Operating Cash Flow1.53B-3.49B1.69B2.25B1.34B950.05M
Investing Cash Flow-82.31M12.08B-419.30M-170.25M517.04M166.44M
Financing Cash Flow-1.58B-7.67B-1.28B-2.05B-1.86B-1.19B

Nectar Lifesciences Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price9.98

Price Trends

50DMA10.67Negative
100DMA10.90Negative
200DMA11.50Negative

Market Momentum

MACD-0.13Positive
RSI40.76Neutral
STOCH18.58Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 9.98 is below the 20-day moving average (MA) of 10.32, below the 50-day MA of 10.67, and below the 200-day MA of 11.50, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 18.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:NECLIFE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:IOLCPIN:IOLCP72OutperformINR 56.27B27.71―0.52%26.76%75.41%
IN:NEULANDLABIN:NEULANDLAB60NeutralINR 270.62B59.83―0.16%50.46%88.44%
IN:GRANULESIN:GRANULES59NeutralINR 199.33B27.72―0.22%21.75%36.70%
IN:HIKALIN:HIKAL57NeutralINR 27.35B-555.15―0.27%8.93%-149.51%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:SOLARAIN:SOLARA50NeutralINR 30.74B82.98――27.30%456.80%
IN:NECLIFEIN:NECLIFE47NeutralINR 1.94B-2.94――-99.85%78.93%

* Healthcare Sector Average

Performance Comparison

0%50%100%IN:NECLIFEIN:GRANULESIN:HIKALIN:IOLCPIN:NEULANDLABIN:SOLARADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NECLIFE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NECLIFENectar Lifesciences Ltd.9.98-4.10-29.12%
IN:GRANULESGranules India Limited804.40272.9151.35%
IN:HIKALHikal Limited221.854.221.94%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.191.70100.13109.35%
IN:NEULANDLABNeuland Laboratories Ltd.21092.604864.3029.97%
IN:SOLARASolara Active Pharma Sciences Ltd.639.30116.9522.39%

Nectar Lifesciences Ltd. Corporate Events

Nectar Lifesciences Issues Revised AGM Proceedings, Receives Clean Audit for FY 2025-26

Sep 19, 2026

Nectar Lifesciences has issued revised proceedings for its 31st Annual General Meeting after correcting an inadvertent error in the cut-off date, reaffirming its adherence to SEBI listing regulations. The AGM was conducted on September 18, 2026 via v...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026